Biopharmaceuticals India, a global values-based, R&D-driven biopharmaceutical leader showcased its cutting-edge digital innovations at the G20 Health Working Group meeting, held in Goa, India, from April 17th to April 19th.

The G20 Health Working Group is a forum that brings together health experts and policymakers from the world's 20 largest economies to discuss key health issues and develop policy recommendations. Dr. Mansukh Mandaviya, Union Health Minister, Government of India, inaugurated the digital health exhibition.

The G20 meeting's focus was ‘Citizen-Centric Health Delivery Ecosystems for Universal Health Coverage leveraging Digital Health and Innovations,’ where discussions were held on creating a digital health ecosystem, innovations in healthcare, technology aiding continuing care, and digital public health goods. The meeting was attended by representatives of G20 member countries, special invitee countries, and relevant international organizations.

“We are truly honored to be part of the prestigious G20 event which is aimed at achieving a collaborative effort to deal with the world’s most pressing health challenges, said Serina Fischer, General Manager of Takeda Biopharmaceutical India. 

“At Takeda, we are committed to meeting the unmet needs of patients by discovering and delivering life-transforming treatments and innovative solutions. India is a key country for our company, and we look forward to connecting and exploring synergies to achieve Universal Healthcare for All for a healthier and brighter world through our participation in this platform. We firmly believe that healthcare is a fundamental right for every individual, and we applaud this platform for bringing together meaningful dialogues toward this goal. Under the presidency of India, we at Takeda are optimistic about the positive and long-lasting impact.” "

Data and technology have the power to transform the way we approach healthcare. At Takeda, we are committed to leveraging advanced analytics, artificial intelligence, and digital solutions to accelerate and enhance patient care and improve health outcomes. By combining our deep scientific expertise with cutting-edge technology, we can create a brighter future for patients and the healthcare ecosystem." said Gabriele Ricci, Chief Data and Technology Officer, Takeda Pharmaceutical Company Limited.

Emphasizing the significance of digital innovations in healthcare, Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceutical India, said, “The very ethos of our company is focused on meeting the unmet needs of the patients and we are proud to be a part of this G20 gathering. Digital innovations have transformed virtually every aspect of our lives, and healthcare is no exception. The potential benefits of these innovations are enormous, including improved patient outcomes, increased access to care, and more efficient healthcare delivery. In a world that is recuperating from a global pandemic, a collaborative effort to address every unmet health concern becomes a priority. Our participation in the G20 Health working group meeting provided a platform to showcase our capabilities and explore potential collaborations with G20 member countries.” 

"At Takeda, we are committed to leveraging digital solutions to transform healthcare”, said Puneet Chopra, Head – Data, Digital and Technology, Takeda Biopharmaceutical India, "Our innovative solutions, MyPKFit, SYNAPSE, and Athena, are aimed at improving patient outcomes and advancing healthcare access. We are excited to have showcased our digital capabilities at the G20 meeting and explore opportunities to collaborate with stakeholders to drive digital health innovation and adoption."